Over-representation of the G12S polymorphism of the SDHD gene in patients with MEN2A syndrome

Clinics

Volumn 67, Issue SUPPLEMENT, 2012, Pages 85-89

  Lendvai, Nikoletta ^a   Tóth, Miklos ^a   Valkusz, Zsuzsanna ^b   Beko, Gabriella ^a   Szücs, Nikolette ^a   Csajbók, Éva ^b   Igaz, Péter ^a   Kriszt, Balázs ^c   Kovács, Balázs ^c   Rácz, Károly ^a   Patócs, Attila ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c SZENT ISTVÁN UNIVERSITY   (Hungary)

Author keywords

Medullary thyroid cancer; Pheochromocytoma; RET proto oncogene; Succinate dehydrogenase subunit D

Indexed keywords

CALCITONIN; PROTEIN RET; RET PROTEIN, HUMAN; SDHD PROTEIN, HUMAN; SUCCINATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CHILD; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PHEOCHROMOCYTOMA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIPPLE SYNDROME; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; CALCITONIN; CHILD; FEMALE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PHENOTYPE; PHEOCHROMOCYTOMA; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTO-ONCOGENE PROTEINS C-RET; SUCCINATE DEHYDROGENASE; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84863928814     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(Sup01)15     Document Type: Article

References (29)

1. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363(6428):458-60, http://dx.doi.org/10.1038/363458a0.
2. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575-9, http://dx.doi.org/10.1001/jama.1996.03540190047028.
3. Mulligan LM, Eng C, Attie T, Lyonnet S, Marsh DJ, Hyland VJ, et al. Diverse phenotypes associated with exon 10 mutations of the RET protooncogene. Hum Mol Genet. 1996;3(12):2163-7, http://dx.doi.org/10.1093/hmg/3.12.2163.
4. Borrego S, Saez ME, Ruiz A, Gimm O, López-Alonso M, Antiñolo G, et al. Polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet. 1999;36(10):771-4.
5. Robledo M, Gil L, Pollan M, Cebrián A, Ruíz S, Azañedo M, et al. Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res. 2003;63(8):1814-7.
6. Lesueur F, Cebrian A, Robledo M, Niccoli-Sire P, Svensson KA, Pinson S, et al. Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Res. 2006;66(2):1177-80, http://dx.doi.org/10.1158/0008-5472.CAN-05-2995.
7. Tamanaha R, Camacho CP, Pereira AC, da Silva AM, Maciel RM, Cerutti JM. Evaluation of RET polymorphisms in a six-generation family with G533C RET mutation: specific RET variants may modulate age at onset and clinical presentation. Clin Endocrinol (Oxf). 2009;71(1):56-64, http://dx.doi.org/10.1111/j.1365-2265.2008.03491.x.
8. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69(2):49-54, http://dx.doi.org/10.1086/321282.
9. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26(3):268-70.
10. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287(2):848-51, http://dx.doi.org/10.1126/science.287.5454.848.
11. Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science. 2009;325(17):1139-42, http://dx.doi.org/10.1126/science.1175689.
12. Hirawake H, Taniwaki M, Tamura A, Amino H, Tomitsuka E, Kita K. Characterization of the human SDHD gene encoding the small subunit of cytochrome b (cybS) in mitochondrial succinate-ubiquinone oxidoreductase. Biochim Biophys Acta. 1999;1412(3):295-300, http://dx.doi.org/10.1016/S0005-2728(99)00071-7.
13. Montani M, Schmitt AM, Schmid S, Locher T, Saremaslani P, Heitz PU, et al. No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma. Endocr Relat Cancer. 2005;12(4):1011-6, http://dx.doi.org/10.1677/erc.1.00996.
14. Ni Y, Zbuk KM, Sadler T, Patocs A, Lobo G, Edelman E, et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet. 2008;83(2):261-8, http://dx.doi.org/10.1016/j.ajhg.2008.07.011.
15. Lima J, Teixeira-Gomes J, Soares P, Maximo V, Honavar M, Williams D, et al. Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. J Clin Endocrinol Metab. 2003;88(10):4932-7, http://dx.doi.org/10.1210/jc.2002-030008.
16. Patócs A, Valkusz Z, Igaz P, Balogh K, Tóth M, Varga I, et al. Segregation of the V804L mutation and S836S polymorphism of exon 14 of the RET gene in an extended kindred with familial medullary thyroid cancer. Clin Genet. 2003;63(3):219-23, http://dx.doi.org/10.1034/j.1399-0004.2003.00044.x.
17. Patócs A, Karádi E, Tóth M, Varga I, Szücs N, Balogh K, et al. Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre. Eur J Cancer Prev. 2004;13(5):403-9, http://dx.doi.org/10.1097/00008469-200410000-00008.
18. Gergics P, Patocs A, Toth M, Igaz P, Szucs N, Liko I, et al. Germline VHL gene mutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateral pheochromocytomas. Eur J Endocrinol. 2009;161(3):495-502, http://dx.doi.org/10.1530/EJE-09-0399.
19. Cranston AN, Ponder BA. Modulation of medullary thyroid carcinoma penetrance suggests the presence of modifier genes in a RET transgenic mouse model. Cancer Res. 2003;63(16):4777-80.
20. Baumgartner-Parzer SM, Lang R, Wagner L, Heinze G, Niederle B, Kaserer K, et al. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab. 2005;90(11):6232-6, http://dx.doi.org/10.1210/jc.2005-1278.
21. Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lari R, et al. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab. 2004;89(7):3579-84, http://dx.doi.org/10.1210/jc.2003-031898.
22. Gimm O, Neuberg DS, Marsh DJ, Dahia PL, Hoang-Vu C, Raue F, et al. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene. 1999;18(6):1369-23, http://dx.doi.org/10.1038/sj.onc.1202418.
23. Cebrian A, Lesueur F, Martin S, Leyland J, Ahmed S, Luccarini C, et al. Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90(11):6268-74, http://dx.doi.org/10.1210/jc.2004-2449.
24. Berard I, Kraimps JL, Savagner F, Murat A, Renaudin K, Nicolli-Sire P, et al. Germline-sequence variants S836S and L769L in the RE arranged during Transfection (RET) proto-oncogene are not associated with predisposition to sporadic medullary carcinoma in the French population. Clin Genet. 2004;65(2):150-2, http://dx.doi.org/10.1111/j.0009-9163.2004.00172.x.
25. Wohllk GN, Soto CE, Bravo AM, Becker CP. G691S, L769L and S836S ret proto-oncogene polymorphisms are not associated with higher risk to sporadic medullary thyroid carcinoma in Chilean patients. Rev Med Chil. 2005;133(4):397-402.
26. Cascon A, Cebrian A, Pollan M, Ruiz-Llorente S, Montero-Conde C, Leton R, et al. Succinate dehydrogenase D variants do not constitute a risk factor for developing C cell hyperplasia or sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90(4):2127-30, http://dx.doi.org/10.1210/jc.2004-2059.
27. Cascon A, Ruiz-Llorente S, Cebrian A, Leton R, Telleria D, Benitez J, et al. G12S and H50R variations are polymorphisms in the SDHD gene. Genes Chromosomes Cancer. 2003;37(2):220-1, http://dx.doi.org/10.1002/gcc.10212.
28. Taschner PE, Jansen JC, Baysal BE, Bosch A, Rosenberg EH, Bröcker-Vriends AH, et al. Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. Genes Chromosomes Cancer. 2001;31(3):274-81, http://dx.doi.org/10.1002/gcc.1144.
29. Waldmann J, Langer P, Habbe N, Fendrich V, Ramaswamy A, Rothmund M, et al. Mutations and polymorphisms in the SDHB, SDHD, VHL, and RET genes in sporadic and familial pheochromocytomas. Endocrine. 2009;35(3):347-55, http://dx.doi.org/10.1007/s12020-009-9178-y.